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Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. Until the
recent discovery of the rapid onset antidepressant action of ketamine, pharmacological
treatments for MDD were limited to conventional antidepressant drugs with delayed clinical
efﬁcacy. Using a judgement bias task, this study has investigated whether the temporal
differences observed in patients would be reﬂected in affective biases and decision making
behaviour in rodents. The diffusion model was also used to investigate the underlying decision
making processes. Positive biases were induced in this task over timeframes that mirror the
rapid versus delayed antidepressant efﬁcacy of the drugs in clinical populations. Diffusion
modelling revealed that the antidepressants tested also have different effects on decision
making processes, suggesting they may act through different neurobiological substrates. This
combination of behaviour and computational modelling may provide a useful approach to
further investigate the mechanisms underlying rapid antidepressant effect and assess potential
new treatments.
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nces Building, Tankards Close,
bristol.ac.uk (E.S.J. Robinson).1. Introduction
In major depressive disorder (MDD), impairments in emotional
processing lead to biases in cognitive processes (Murphy
et al., 1999; Robinson et al., 2011; Roiser et al., 2012). The
importance of these biases in MDD was ﬁrst proposed by Beck
in his cognitive theory of depression (Beck, 1976). Moreen access article under the CC BY license
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ment, maintenance and treatment of MDD (Teasdale,
1983, 1988; Beck, 2008; Harmer et al., 2009a; Kircanski
et al., 2012). Processes including attention, memory, emo-
tional interpretation and decision making have been shown
to be negatively biased in people suffering from MDD
(see Mathews and MacLeod, 2005; Clark et al., 2009; Gotlib
and Joormann, 2010 for in-depth reviews). Treatment with
antidepressants, including acute doses, induce positive biases
in emotional processing in healthy controls (Harmer
et al., 2003, 2004, 2011) and patients (Harmer et al.,
2009b). However, this does not match the subjective
experience of patients, where changes in mood are only
reported several weeks after starting conventional antide-
pressant treatment (Anderson et al., 2000). In contrast,
patients experience a subjective improvement in mood less
than two hours after administration of the rapid-acting
antidepressant ketamine (Zarate et al., 2006).
Understanding the processes which underlie delayed
versus rapid onset antidepressant action is important if
new faster acting treatments are to be developed. Different
theories exist to explain the delayed onset of action of
conventional antidepressants (Duman and Monteggia, 2006;
Harmer et al., 2009a; Harmer, 2010; Duman and Li, 2012;
Wang et al., 2015). The different time course of efﬁcacy has
been related to ketamine's ability to quickly increase
synaptogenesis and density and function of spine synapses
via rapid glutamatergic effects on intracellular signalling
pathways (Duman et al., 2012). This is in comparison to the
longer-term neuroplasticity and neurogenic changes that
are produced by slow-onset adaptation of signalling path-
ways through conventional antidepressants acting on neu-
romodulatory (e.g. serotonergic) systems (Duman and
Voleti, 2012). However, in rodent behavioural tests such as
the forced swim test, both ketamine (Browne and Lucki,
2013) and conventional antidepressants (Porsolt et al.,
1977; Cryan and Holmes, 2005) demonstrate efﬁcacy
after acute administration. Another commonly used rodent
test for antidepressant efﬁcacy, the sucrose preference
test, can differentiate between delayed and rapid onset
antidepressants but only when used in combination
with a chronic stress manipulation (Willner, 2005; Browne
and Lucki, 2013). This highlights the limitations of current
animal models used to quantify depression-like beha-
viour, and concerns have been raised that the poor transla-
tion between pre-clinical studies and clinical beneﬁts
may relate to these issues (for discussion see Nestler
et al., 2002; Cryan and Slattery, 2007; Nestler and
Hyman, 2010; Berton et al., 2012; O'Leary and
Cryan, 2013). The assessment of animal models of depres-
sion against the criteria of face, construct and predi-
ctive validity indicates that these assays may be limited
to tests of monoaminergic antidepressant efﬁcacy and
fail to achieve either construct or predictive validity
(Willner, 1984; Belzung and Lemoine, 2011). Identiﬁcation
of an animal test that could dissociate delayed and rapid
antidepressant onset of action without the need for chronic
stress procedures would provide a vital tool for the drug
discovery process.
Building on research in humans, tests to study affective
biases in animals have been developed, which include theaffective bias test (Stuart et al., 2013, 2015) and judgement
bias tasks (see Hales et al., 2014 for a review). Evidence
from studies using phenotypic models and drug treatments
suggest that in non-human species these tasks can be used
to quantify similar neuropsychological processes linked to
affective biases. The judgement bias task is designed to
more closely mirror the type of neuropsychological impair-
ments seen in depression (Hales et al., 2014; Robinson and
Roiser, 2016) and therefore achieves better face validity
than traditional tests. The cause of depression remains
unknown and therefore achieving construct validity is more
difﬁcult. Evidence from animals in putative depression-like
states following chronic stress manipulations have revealed
pessimistic behaviour in the judgement bias task (Harding
et al., 2004; Papciak et al., 2013; Rygula et al., 2013) which
is similar to the negative interpretation biases observed in
depressed patients (e.g. Butler and Mathews, 1983;
Nunn et al., 1997; Voncken et al., 2007). We have previously
shown effects on biases in this task with chronic
monoaminergic antidepressant treatment (Anderson
et al., 2013), whilst experiments to date have generally
failed to observe consistent effects with conventional
antidepressants following acute administration (Anderson
et al., 2013; Rygula et al., 2014a).
In the affective bias test in rats, a dissociation between
delayed and rapid onset antidepressants has been shown in
terms of their effects on learning and memory (Stuart et al.,
2013, 2015). Where conventional antidepressants can
induce positive biases associated with new learning but lack
the ability to attenuate previously acquired negative biases,
ketamine was observed to have the opposite effect. This
study focuses on investigating the predictive validity of the
judgement bias task, speciﬁcally comparing the efﬁcacy and
time course of effects for delayed versus rapid onset
antidepressants on judgement bias, and whether this con-
curs with their reported clinical outcomes in patients. We
hypothesised that this task may provide a novel behavioural
approach which could be used to dissociate between
delayed and rapid onset antidepressants.
The diffusion model (Ratcliff, 1978; Ratcliff and Rouder, 1998)
provides insight into the processes that underlie decision making
by parameterising the subtle differences in shapes of response
time (RT) distributions from behavioural two-choice decision
making data. These parameters are associated with psychologi-
cally meaningful processes (Ratcliff, 1978). The diffusion model
assumes that decision making begins at a relative starting point
(zr) that is located somewhere between two boundaries (a
and 0), each representing one of the two alternative responses.
Information accumulates over time from the starting point until
one or other threshold is reached. Therefore, the starting point
determines the amount of information that is required before a
decision is made. The rate of this information accumulation
(known as the drift rate, v) is governed by the quality of the
stimuli, in that if incoming information is of high quality, the
drift rate will be steeper and so a boundary (and hence decision)
will be reached more quickly. Therefore, changes in the drift
rate reﬂect changes in discrimination difﬁculty (when compared
between trial types) or perceptual sensitivity (when compared
across different conditions). Other parameters in the model
include the time taken for non-decision processes (t0), para-
meters quantifying the variability in starting point, drift rate and
C.A. Hales et al.1270non-decision time (szr, sv and st0 respectively) and a parameter
that accounts for possible differences in the speed of response
execution between the two choices (d).
Advantages of using a diffusion modelling approach over
and above traditional analyses of behavioural data include:
being able to disentangle the different factors that may
alter decision making (e.g. response conservatism, percep-
tual factors or the inﬂuence of various biases; (Voss et al.,
2013a, 2013b); using maximal information from behavioural
data to provide a more thorough interpretation of results
(as both RT and accuracy data are incorporated together in
the model; White et al., 2009, 2010; Voss et al., 2013a); and
increased sensitivity to detecting experimentally induced
changes that may be split across both RT and accuracy in
behavioural data (White et al., 2010).
To investigate whether a reward-based judgement bias
task can dissociate between delayed and rapid onset anti-
depressants we tested the effects of acute treatments with
conventional, delayed onset antidepressants: ﬂuoxetine (a
selective serotonin reuptake inhibitor; SSRI), reboxetine (a
noradrenaline reuptake inhibitor, NRI) and venlafaxine (a
serotonin and noradrenaline reuptake inhibitor, SNRI); ver-
sus the rapid-acting antidepressant, ketamine (an N-methyl-
D-aspartate (NMDA) receptor antagonist) and phencyclidine
(PCP), another NMDA receptor antagonist with no known
antidepressant properties. For comparison, we also tested
two psychostimulants, amphetamine and cocaine, which are
known to induce hedonic effects following acute adminis-
tration. Following the acute drug studies, a ﬁnal experiment
investigated the effect of chronic treatment (three weeks)
with ﬂuoxetine. We used a reward-based ambiguous cue
interpretation task to measure judgement bias, and applied
the diffusion model to behavioural results to add to the
interpretation of the data (Hales et al., 2016).2. Experimental procedures
2.1. Subjects and apparatus
Three cohorts of male Lister Hooded rats (cohort 1: n=16; cohort 2:
n=18; cohort 3: n=16) were used (Harlan, UK). Rats weighed 270
to 300 g at the start of training, and 400 to 500 g at the start of
experimental manipulations. They were pair-housed with environ-
mental enrichment consisting of a red Perspex house, a cardboard
tube and a cotton rope suspended across the cage lid. Rats were
kept under temperature (19–23 1C) and humidity (45–65%) con-
trolled conditions on a 12-h reverse lighting cycle (lights off at
08:00 h). Water was available ad libitum in the home cage, but rats
were maintained at no less than 90% of their free-feeding body
weight by restricting access to laboratory chow (LabDiet, PMI
Nutrition International) to 18 g per rat per day. All procedures
were carried out under local institutional guidelines (University of
Bristol Animal Welfare and Ethical Review Board) and in accordance
with the UK Animals (Scientiﬁc Procedures) Act 1986. During
experiments all efforts were made to minimise suffering, and at
the end of experiments rats were euthanised by giving an overdose
of sodium pentobarbitone. Behavioural testing was carried out
between 0800 and 1800 h, using standard rat operant chambers
(Med Associates, Sandown Scientiﬁc, UK). For details of operant
chamber conﬁguration, see Supplementary Materials and Methods.2.2. Behavioural task
Animals were tested using a high versus low reward version of the
ambiguous interpretation task as previously reported in Hales et al.
(2016). Rats were trained to associate a correct response to two
different auditory tones with either a high or low value reward.
Responses made following a midpoint ambiguous tone were used to
measure judgement bias.
2.2.1. Training: cohort 1
Rats (n=16) in cohort 1 were trained to associate one tone (2 or
8 kHz at 75 and 64 dB respectively; counterbalanced across rats,
designated high reward) with a large food reward (four 45 mg
reward pellets; Test Diet, Sandown Scientiﬁc, UK) and the other
tone (8 or 2 kHz, the opposite of the high reward tone, designated
low reward) with a small food reward (one 45 mg reward pellet) if
they pressed the associated lever (either left or right, counter-
balanced across rats) during the 20 s tone. Table S1 contains a
summary of training stages used. Once trained, these animals were
used to test the acute effects of three conventional antidepressants
– ﬂuoxetine, reboxetine and venlafaxine.
2.2.2. Training: cohorts 2 and 3
As rats in cohort 1 tended to show an innate bias towards the higher
frequency tone and preference for the higher value reward
(See Figure S6 for details), the second and third cohorts were not
trained using a fully counter-balanced design. Instead, the 2 kHz
tone was associated with the high reward for all rats (n=18/n=16).
This reduced variability and improved sensitivity to detect altered
responding to the midpoint ambiguous tone. Any innate biases were
accounted for by using the animals own baseline to normalise data
for cognitive bias index (CBI; see Statistical Analysis for details). All
other training remained the same as for cohort 1 (See Table S1).
Once trained, cohort 2 was used to test the acute effects of
ketamine, PCP, amphetamine and cocaine. After the last acute
study, rats were given at least two weeks washout before being split
into two groups to allow for chronic treatment with ﬂuoxetine
(1.0 mg/kg daily) or vehicle. Cohort 3 were used for a replication
study testing the effect of a single acute dose of 1.0 mg/kg
ketamine.
2.2.3. Ambiguous cue interpretation testing
Baseline sessions (100 trials: 50 high and 50 low reward tones;
pseudorandomly) were conducted on Monday and Thursday. Probe
test sessions (120 trials: 40 high reward, 40 low reward, and 40
ambiguous midpoint tones; pseudorandomly) were conducted on
Tuesday and Friday. The ambiguous midpoint tone was made up of
one of two tones (20 4999 Hz and 20 5001 Hz at 70 dB). The
outcomes associated with the ambiguous tones were the same as
the reference tone they were closer to, resulting in a random
reinforcement of the midpoint tone. This meant a speciﬁc outcome
should not be learnt for the midpoint tone, and ensured continued
responding throughout the experiments. Responses to either of the
two midpoint tones were analysed together. For further task details
see Supplementary Materials and Methods. Rats were considered
trained when they maintained stable responding for three con-
secutive days, and were excluded from analyses if they failed to
maintain 460% accuracy during experiments.
2.3. Experimental design
2.3.1. Acute drug treatments
Each acute dose-response study used a within-subject fully counter-
balanced drug treatment schedule (See Table S2 for details of
individual treatments). All drugs were dissolved in 0.9% sterile
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injection using a low-stress, non-restrained technique (Stuart and
Robinson, 2015). For testing the effect of acute antidepressant
treatment, ﬂuoxetine (0.3, 1.0 mg/kg), reboxetine (0.3, 1.0 mg/
kg), venlafaxine (1.0, 3.0 mg/kg) or vehicle (0.0 mg/kg) were
administered 30 min prior to the probe test session (all purchased
from Tocris, UK). For all other studies, the experimenter was
blinded to drug dose. For acute drug studies in cohort 2, each
dose-response occurred across two weeks with three drug doses
plus vehicle (0.0 mg/kg). Ketamine (0.3, 1.0, 3.0 mg/kg; t=60
min), amphetamine (0.1, 0.3, 1.0 mg/kg; t=15 min) and cocaine
(0.3, 1.0, 3.0 mg/kg; t=10 min) were purchased from Sigma-
Aldrich, UK; PCP (0.3, 1.0, 3.0 mg/kg; t=40 min) was purchased
from Tocris, UK. In cohort 3, the ketamine replication (1.0 mg/kg,
t=60 min; Sigma-Aldrich, UK) occurred over one week. Drug
doses were selected based on previous rodent behavioural studies
(Stuart et al. 2013, 2015; Benn and Robinson 2014). Rats experi-
enced at least one week re-baseline (ﬁve baseline sessions)
between each experimental manipulation.
2.3.2. Chronic ﬂuoxetine treatment
A between-subjects study design was used, and the experiment was
split into three parts: (1) a pre-drug week, (2) three weeks of drug
treatment, and (3) one week post-drug testing. Rats were split into
control (0.9% sterile saline vehicle) or ﬂuoxetine (1.0 mg/kg) groups
based on performance (matched for all analysed behavioural
variables) during the pre-drug week. Rats were dosed daily at least
3 h following the end of behavioural testing by subcutaneous
injection, commencing the Monday of ﬁrst drug week and ending
on the Thursday of ﬁnal drug week.
2.4. Modelling
The diffusion model (Ratcliff, 1978) provides insight into the
cognitive processes that underlie decision making on two-choice
tasks by ﬁtting parameters that correspond to different aspects of
the decision making process (see Ratcliff and Rouder, 1998 for a
detailed description of the model). This means it can distinguish
between different factors that may affect decision making (e.g.
interpretation of sensory information or the inﬂuence of biases), as
these map on to different parameters. The model takes into
account the full shape of response time (RT) distributions and
accuracy data simultaneously, meaning maximal information can be
extracted from behavioural data. Since the model describes RT
distributions as well as accuracy data, behaviours with the same
accuracy, for example, can correspond to different model para-
meters, reﬂecting different RT distributions. This means the diffu-
sion model is more sensitive to detecting subtle changes,
particularly if experimental manipulations cause changes that
manifest across both RT and accuracy measures (Voss et al., 2004).
The diffusion model was ﬁt using fast-dm-30 (Voss and Voss, 2007,
2008; Voss et al., 2010, 2015) to individual rats’ data from probe test
sessions. Model ﬁtting and validation followed that described pre-
viously (Hales et al., 2016), and further details are provided in
Supplementary Methods and Materials.
2.5. Statistical analysis
CBI was used as a measure of judgement bias in response to the
midpoint tone. CBI was calculated by subtracting the proportion of
responses made on the low reward lever from the proportion of
responses made on the high reward lever. This created a score
between 1 and 1, where negative values represent a negative bias
and positive values a positive bias. Change from baseline in CBI was
then calculated for all experimental manipulations. For acute drugstudies this was calculated as follows: vehicle (0.0mg/kg) probe
test CBI−drug dose probe test CBI and for the chronic manipulation:
average of the two pre-drug probe test CBI-drug/post drug probe
test session CBI
This was calculated to take into account individual differences in
baseline bias, and to make directional changes caused by drug
treatments clearer. Although individuals within a cohort were variable
regarding their CBI scores at baseline, performance was consistent
across repeated sessions (compare the vehicle/pre-test percentage
positive responses panels in Supplementary Figures S2–S5 – these show
the behavioural data used to calculate CBI). To provide a value for
vehicle probe test sessions for this measure, the population average
for the vehicle (0.0 mg/kg) probe test was taken away from each
individual rats’ CBI score for the same session. This allowed this
measure to be analysed with repeated measures analysis of variance
(ANOVA) with session as the within-subjects factor (and group as the
between subjects factor for the chronic manipulation). Based on our a
priori hypotheses, change from baseline in CBI was also analysed with
one-sample t-tests with test values of zero (representing no change
from the vehicle or control probe test session) for each drug dose in
acute studies. For the chronic manipulation, change from baseline in
CBI was also analysed in a separate analysis by week (to reduce the
higher variability in this study due to lower n number per group) by
taking the average of the two probe test sessions for that week.
Response latency and percentages of positive responses, omis-
sions and premature responses were also analysed (see Table S3 for
details of these). For acute manipulations, all measures were
analysed with repeated measures analysis of variance (ANOVAs)
with session and tone as the within-subjects factors. For the chronic
manipulation, mixed ANOVAs were performed with two repeated
measures (session and tone) as the within-subjects factor and group
as the between-subjects factor. This was done initially after the
pre-drug week for the ﬁrst two probe sessions to check that groups
were matched for all analysed behavioural variables, and then
subsequent analysis following completion of the study was also
conducted using all three experimental periods (pre-drug, drug and
post-drug).
Diffusion model parameters analysed were change from baseline in
relative starting point (zr; as described for change from baseline in
CBI), drift rate (v) and boundary separation (a) for the midpoint tone.
For the chronic manipulation, parameter values from individual
sessions from each part (pre-drug, drug and post-drug) were
averaged.
Paired t-tests or independent samples t-tests were performed as
post-hoc tests if signiﬁcant effects were established. Huynh-Feldt
corrections were used to adjust for violations of the sphericity
assumption, Levene's test was used to correct for inequality of
variances, and Bonferroni correction was applied for multiple com-
parisons. All statistical tests were conducted using SPSS 21.0.0.0 for
Windows (IBM SPSS Statistics) with α=0.05. Results are reported with
the ANOVA F-value (degrees of freedom, error) and p-value as well as
any post-hoc p-values. All graphs were made using Graphpad Prism
5.03 for Windows (Graphpad Software, USA).
3. Results
3.1. Acute effects of conventional, delayed onset
antidepressants
Nine rats attained criteria and were included in the analysis.
None of the drugs tested signiﬁcantly altered judgement bias
(no main effect of session: F3.175,25.396=0.725, p=0.554;
Figure 1A), although there was a tendency for 0.3 mg/kg
reboxetine to cause a negative change from baseline in
cognitive bias index (CBI; one sample t-test: p=0.070;
C.A. Hales et al.1272Figure 1A). The 1.0 mg/kg dose of reboxetine increased
response latency for the midpoint and low reward tones
(Figure S1A). There were no other effects on behavioural
measures (Figure S1B–D). Diffusion modelling revealed that
the higher doses of reboxetine (1.0 mg/kg) and venlafaxine
(3.0 mg/kg) caused a positive change from baseline in
relative starting point (one sample t-tests: psr0.043;
Figure 1B). There were no effects on drift rate (Figure 1C),
but the boundary was increased compared to vehicle for
1.0 mg/kg reboxetine (main effect of session: F6,42=3.574,
p=0.006 and pairwise comparison: p=0.032; Figure 1D).
Reboxetine (1.0 mg/kg) caused a decrease in the variability
of the decision starting point (Table S4).
3.2. Acute effects of NMDA receptor antagonists
Thirteen rats met criteria to be included in the analysis of
the ketamine dose response. There was no overall main
effect of ketamine on change from baseline in CBI
(F2.114,25.372=0.953, p=0.403), but the 1.0 mg/kg dose
showed a positive change from baseline in CBI measured
using the one-sample t-test (p=0.012; Figure 2A). The other
two doses caused changes of a similar magnitude but with
higher variability (0.3 mg/kg: p=0.145; 3.0 mg/kg:
p=0.187). There were no other effects on behavioural
measures (Figure S2). Diffusion modelling revealed theFigure 1 The effect of acute treatment with three antidepressa
(0.3, 1.0 mg/kg), reboxetine (0.3, 1.0 mg/kg), venlafaxine (1.0, 3.0
prior to testing on the judgement bias task. (A) None of the ant
cognitive bias index (CBI) for the midpoint tone. Although not sign
negative change in CBI. (B/C/D) Behavioural data were modelled u
relative starting point (zr), drift rate (v) and boundary separation (a
and venlafaxine (3.0 mg/kg) caused a positive change in zr. (C) T
(1.0 mg/kg) only caused a signiﬁcant increase in a. Change from ba
account individual differences in underlying bias. Data shown are
30 min pre-treatment. *po0.05, #pr0.07. Veh – vehicle; Flu – ﬂuodrift rate was less negative compared to vehicle for the
1.0 mg/kg dose (main effect of session: F3,36=2.918,
p=0.047 and post-hoc test: p=0.034; Figure 2C). Ketamine
did not alter any other diffusion model parameters
(Figure 2B/D; Table S4).
Fifteen rats were included in the single dose ketamine
replication study. There was a session*tone interaction for
percentage of positive responses (F2,28=3.367, p=0.049)
which post-hoc tests revealed to be because ketamine
(1.0 mg/kg) caused an increase in responses made on the
high reward lever for the midpoint tone only (p=0.022;
Figure S2). This reduction in negative judgement bias was
also apparent in the change from baseline in CBI (one-
sample t-test: p=0.022; Figure 2A). There were no changes
to other behavioural measures (Figure S2). Diffusion model
results were also replicated, where 1.0 mg/kg ketamine
caused the drift rate to become less negative (main effect
of session: F1,14=4.926, p=0.043 and post-hoc test:
p=0.047; Figure 2C), but did not alter other parameters
(Figure 2B/D; Table S4).
Sixteen rats were included in the analysis for the PCP
dose response study. No effects on CBI were observed for
any of the doses tested (main effect of session: F3,45=0.493,
p=0.689; one-sample t-tests: psZ0.170; Figure 3A). The
highest dose (3.0 mg/kg) caused slower response latencies
for all tones (Figure S3A) and increased percentagents on behaviour and modelling of judgement bias. Fluoxetine
mg/kg) or saline vehicle (0.0 mg/kg) were administered acutely
idepressants tested at any dose induced a positive change in
iﬁcant, reboxetine (0.3 mg/kg) showed a tendency to cause a
sing the diffusion model and parameters corresponding to the
) were analysed. (B) The higher doses of reboxetine (1.0 mg/kg)
here were no effects on v. (D) The higher dose of reboxetine
seline (vehicle session) measures were calculated to take into
for the midpoint tone only, and represent mean 7 SEM. n=9,
xetine; Reb – reboxetine; Ven – venlafaxine.
Figure 2 The effect of acute treatment with ketamine on behaviour and modelling of judgement bias. Ketamine (0.0, 0.3, 1.0,
3.0 mg/kg) was administered acutely prior to testing on the task. Behavioural data were modelled using the diffusion model and
parameters corresponding to the relative starting point (zr), drift rate (v) and boundary separation (a) were analysed. (A) Acute
treatment with ketamine (1.0 mg/kg), a rapid acting antidepressant, induced a positive bias at the midpoint tone. (B) Ketamine had
no effect on zr. (C) The positive bias induced by 1.0 mg/kg ketamine is reﬂected by a more positive drift rate (v). (D) Acute
treatment with ketamine did not alter (a). Change from baseline (0.0 mg/kg session) measures were calculated to take into account
individual differences in underlying bias. Data shown are for the midpoint tone only, and represent mean7SEM. n=13, 60 min pre-
treatment. *po0.05.
1273Behavioural and computational methodsomissions for the midpoint and low reward tones (Figure
S3C), while 1.0 mg/kg PCP increased premature responding
(Figure S3D). Consistent with the increased response
latency, the highest dose of PCP (3.0 mg/kg) increased
boundary separation (main effect of session: F3,45=5.775,
p=0.002 and post-hoc test: p=0.002; Figure 3D) and the
non-decision reaction time (Table S4). There were no other
effects on diffusion model parameters (Figure 3B/C and
Table S4).3.3. Effect of chronic treatment with ﬂuoxetine
Seventeen rats (n=9 control, n=8 ﬂuoxetine) were included
in the analysis. There were no differences between the
control and ﬂuoxetine group for any variables analysed in
the two pre-drug probe test sessions (Figure 4D–F, Figure S4
and Table S4). Overall analysis of the entire study period
(pre-drug, drug and post-drug) did not show any main effects
on change in CBI, although there was a trend towards a group
difference (F1,15=3.895, p=0.067), which when analysed
excluding the pre-drug period (as measures for this period
were matched between groups) indicated that the ﬂuoxetine
group become more positive relative to the control group
during the treatment period only (main effect of session:
F4.82,72.31=4.724, p=0.002, and signiﬁcant group difference
during sessions 3–8 (drug period): F1,15=6.642, p=0.021;
Figure 4A). However, there were no signiﬁcant differences
for individual sessions during the treatment period in post-
hoc comparisons. In the ﬁrst probe test following cessation of
treatment (4 days later; session 9 in the post-drug period of
Figure 4A), this difference between groups was no longer
apparent. A separate analysis of the drug period by weekindicated that the ﬂuoxetine group were not more positive
than controls immediately following onset of antidepressant
treatment, instead only becoming different in weeks 2 and 3
(independent samples t-tests: psr0.048; Figure 4B). Chronic
ﬂuoxetine treatment did not alter any other behavioural
measure (Figure S4). Chronic antidepressant treatment did
not signiﬁcantly alter any diffusion model parameters in the
overall analysis (Figure 4C/E/F and Table S4). However,
analysing change in relative starting point by week showed
that as for the behaviour, in weeks two and three this
parameter became more positive in the ﬂuoxetine group
compared to the control group (independent sample t-tests:
psr0.039; Figure 4D).3.4. Acute effects of psychostimulants
For amphetamine, ﬁfteen rats were included in the analysis.
However, the highest dose (1.0 mg/kg) had to be excluded
from analysis as rats completed insufﬁcient trials. Amphe-
tamine treatment (0.3 mg/kg) caused a positive judgement
bias (main effect of session: F1.535,21.485=4.414, p=0.033
and post-hoc test: p=0.041; positive change from baseline
in CBI; one-sample t-test: p=0.001; Figure 5A). This was
also seen as an increase in percentage positive responding
for the midpoint tone (Figure S5B). This dose caused an
increase in omissions for the low reward tone (Figure S5C).
Both doses of amphetamine caused an increase in prema-
ture responses (Figure S5D) but no changes in response
latency (Figure S5A). The positive judgement bias was
caused by a more positive drift rate (v) for 0.3 mg/kg
compared to vehicle (main effect of session: F2,28=6.444,
p=0.005 and pairwise comparison: p=0.008; Figure 5C), as
Figure 3 The effect of acute treatment with phencyclidine on behaviour and modelling of judgement bias. Phencyclidine
(PCP; 0.0, 0.3, 1.0, 3.0 mg/kg) was administered acutely prior to testing on the task. Behavioural data were modelled using the
diffusion model and parameters corresponding to the relative starting point (zr), drift rate (v) and boundary separation (a) were
analysed. (A) Acute treatment with PCP had no effect on judgement bias. (B/C) PCP did not alter zr or v. (D) The highest dose of PCP
(3.0 mg/kg) caused a signiﬁcant increase in a. Change from baseline (0.0 mg/kg session) measures were calculated to take into
account individual differences in underlying bias. Data shown are for the midpoint tone only, and represent mean7SEM. n=16,
40 min pre-treatment. **po0.01.
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amphetamine (Figure 5B/D and Table S4).
For the cocaine dose response, seventeen rats met
criteria to be included in the analysis. There was no effect
of any dose of cocaine (0.3, 1.0, 3.0 mg/kg) on any
behavioural measure for the midpoint tone (Figure 5E and
Figure S5E–H). Similarly, cocaine did not alter any diffusion
model parameters (Figure 5F–H and Table S4) apart from
3.0 mg/kg cocaine caused the variability in the decision
starting point to increase (Table S4).4. Discussion
These experiments have revealed that delayed versus rapid
onset antidepressant treatments exhibit temporally distinct
effects on emotional decision making in rodents. The time
course of the effects we observed are similar to the time-
scales associated with the subjective reporting of improved
mood in patients. In the judgement bias task, affective bias
was altered following chronic but not acute treatment with
ﬂuoxetine. In contrast, an immediate change was observed
following acute administration of the NMDA antagonist,
ketamine, and the psychostimulant, amphetamine. Another
NMDA antagonist, PCP, had no effect, reﬂecting the lack of
known antidepressant efﬁcacy for this drug.Previous studies have reported acute effects of ketamine in
many rodent models of depression (reviewed by Browne and
Lucki (2013)). However, antidepressant efﬁcacy is also seen in
many of these tests following acute treatment with conven-
tional antidepressants. This contradicts the rate of onset of
efﬁcacy for these drugs. Patients with MDD only report
subjective changes in mood weeks after beginning to take
antidepressants (Anderson et al., 2000), with a meta-analysis
of timing of onset of antidepressant efﬁcacy ﬁnding that the
majority of improvement was apparent after two weeks of
treatment (Posternak and Zimmerman, 2005). Using the
judgement bias task, we observed biases in the positive
direction in decision making over timeframes that match the
rapid versus delayed onset action of the drugs tested, i.e.
immediately after a single acute treatment for ketamine, but
only after two weeks for chronic treatment with ﬂuoxetine. It
must be noted that rats treated with ketamine did not
become positive overall, only less negative than during vehicle
treatment. In clinical trials, ketamine infusions in people
rapidly reduce negative mood (e.g. Zarate et al., 2006) but
it is not clear whether this treatment causes positive mood in
patients or also makes them less negative. This is an area we
hope to explore further in our future work using the judge-
ment bias task.
Similarly, rats treated with chronic ﬂuoxetine were not
more positive relative to their own baseline, but rather only
Figure 4 The effect of chronic treatment with an antidepressant on behaviour and modelling of judgement bias. Rats assigned to
the chronic antidepressant group experienced subcutaneous injections of ﬂuoxetine (1.0 mg/kg) daily for three weeks, whilst
control rats experienced daily subcutaneous injections of saline vehicle (0.0 mg/kg). Twice weekly test sessions were conducted one
week prior to treatment (pre; sessions 1–2), for the three weeks during treatment (drug; sessions 3–8) and for one following the end
of treatment (post; sessions 9–10). There were no signiﬁcant differences between groups during the pre-drug period for any
measure. (A) Rats in the ﬂuoxetine-treated group had a signiﬁcantly more positive change from baseline in cognitive bias index (CBI)
compared to controls during the drug period only. (B) Analysing each week of treatment shows that the more positive change from
baseline in CBI in the ﬂuoxetine group did not occur immediately, instead only becoming apparent during weeks 2 and 3 of
treatment. This difference was no longer apparent following cessation of drug treatment. (C/D/E/F) Behavioural data were
modelled using the diffusion model and parameters corresponding to the relative starting point (zr), drift rate (v) and boundary
separation (a) were analysed. Data shown are averages for all probe sessions during that experimental period. (C) Although not
signiﬁcant, chronic antidepressant treatment showed a tendency to cause a more positive zr. This was both compared to the groups
own baseline, and compared to controls. (D) Analysis of this measure by week indicated that zr was more positive compared to
baseline in weeks 2 and 3, the same weeks that there was a more positive change in CBI. (E) There were no differences in v between
the control and ﬂuoxetine-treated groups. (F) There were also no changes in boundary separation (α). Change from baseline
(average of the two pre-drug test sessions) measures were calculated to take into account individual differences in underlying bias.
Data shown are for the midpoint tone only, and represent mean7SEM. Control group: n=9, ﬂuoxetine-treated group: n=8.
*po0.05, #pr0.09.
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Figure 5 The effect of acute treatment with psychostimulants on behaviour and modelling of judgement bias. Amphetamine
(0.1, 0.3 mg/kg) or cocaine (0.3, 1.0, 3.0 mg/kg) or saline vehicle (0.0 mg/kg) were administered acutely prior to testing on the
judgement bias task. (A/E) Amphetamine (0.3 mg/kg) induced a positive judgement bias, whilst cocaine had no effect. (B/C/D) As
with the positive bias induced acutely by ketamine, diffusion modelling indicated a more positive drift rate was also underlying the
positive bias induced by amphetamine. Amphetamine had no effect on other model parameters. (F/G/H) Cocaine did not alter any
diffusion model parameters. Data shown are for the midpoint tone only, and represent mean7SEM. Amphetamine: n=15, 15 min
pre-treatment; cocaine: n=17, 10 min pre-treatment. **po0.01.
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during the treatment period. This suggests that chronic
antidepressant treatment may not have been inducing a
positive bias, but rather ameliorating a negative bias that
could have been caused through the stress of repeated daily
injections. However, even if this is the case it is clear that it
is only chronic rather than acute antidepressant treatment
where any effect on bias occurs.
The ketamine doses used in these studies were lower than
those often reported to display antidepressant efﬁcacy in
the forced swim test, whilst for the conventional antide-
pressants tested, these doses are in line with 70%
receptor occupancy (Stuart et al., 2013). This task may
therefore provide a novel and sensitive behavioural
approach for detecting rate of onset of antidepressant
treatment in a way which is relevant to how a drug will
affect the subjective experience of mood in people.
The precise details of ketamine's mechanism of rapid
antidepressant action are currently unclear, but our results
suggest that this is not speciﬁc to NMDA receptor antagonism,
as PCP failed to induce any effect. This is in keeping with
clinical observations, where it has been shown that other
NMDA receptor antagonists (e.g. memantine, lanicemine and
MK-0657) do not reliably produce rapid-onset antidepressant
action in patients with MDD (Newport et al., 2015). Zanos
et al. (2016) have recently provided convincing evidence for
the importance of sustained activation of AMPA receptors by
the ketamine metabolite (2S,6S;2R,6R)-hydroxynorketamine.
Other potential target pathways through which ketamine
exerts rapid-onset antidepressant efﬁcacy may include BDNF
(brain-derived neurotrophic factor), mTOR (mammalian target
of rapamycin) and GSK-3 (glycogen synthase kinase 3; (sum-
marised by Drewniany et al. (2015)).
The data derived from diffusion modelling shows that
rapid versus delayed onset antidepressants differ in their
effects on decision making processes, which suggests dif-
ferent underlying neurobiology. A less negative drift rate
was found to explain the positive bias induced acutely by
ketamine whereas a more positive decision starting point
was seen following chronic treatment with ﬂuoxetine.
Furthermore, despite a lack of effect on behaviour, the
higher doses of reboxetine (1.0 mg/kg) and venlafaxine
(3.0 mg/kg) also caused signiﬁcant positive changes in the
decision starting point. The opposite direction of the
decision starting point and behaviour may seem contra-
dictory, but diffusion model parameters are ﬁt to both
accuracy and RT behavioural data, not just CBI. This
suggests that conventional antidepressant drugs act to alter
the neuropsychological processes driving bias via a different
mechanism to rapidly acting drugs. This is also consistent
with ﬁndings from the rodent affective bias test, where
venlafaxine and ketamine have differential effects on biases
associated with learning and memory (Stuart et al., 2015).
The ability of the diffusion model to detect this in both
acute and chronic conventional antidepressant treatments,
even where signiﬁcant behavioural results are not detected,
highlights the advantage of using the more sensitive diffu-
sion modelling approach. Diffusion modelling results from
this study are also consistent with a previous study where a
more negative drift rate was found to underlie negative bias
caused by an acute pharmacological treatment, whereas a
more negative starting point explained negative biasinduced over a longer time period by a chronic stress
manipulation (Hales et al., 2016).
Treatment with two psychostimulant drugs – ampheta-
mine and cocaine – reproduced previously published results
from a reward versus avoidance of punishment version of
this task (Rygula et al., 2014a, 2014b). Amphetamine
(0.3 mg/kg) induced a positive judgement bias, whilst
cocaine had no effect. Although amphetamine and cocaine
both affect monoamine levels in the brain, cocaine has a
great selectively for the dopamine system whereas amphe-
tamine affects noradrenaline, serotonin and dopamine
(McMillen, 1983). It may be that this broader effect on
monoamine levels in the brain contributes to the dissocia-
tion between these two treatments and judgement bias.
The differences between the effects of amphetamine on
judgement bias versus its lack of effect on affective biases
linked with learning and memory (Stuart et al., 2013)
further supports our hypothesis that this task is sensitive
to treatments which induce subjective changes in mood in
humans. As with the positive bias induced acutely by
ketamine, diffusion modelling indicated a more positive
drift rate was also underlying the positive bias induced by
amphetamine. Interestingly, from the 1940s through to the
mid-1960s, amphetamine was quite widely used for its
antidepressant effects due to its ability to rapidly enhance
mood and counteract the effects of anhedonia (Rasmussen,
2006). Both amphetamine and ketamine are psychotomi-
metic drugs, a common factor that may provide an alter-
native explanation for the positive changes in bias.
However, PCP has similar properties but did not cause any
change in bias, meaning this is unlikely to fully explain the
effects on judgement bias observed. Like ketamine, amphe-
tamine has no acute effect on affective biases linked with
learning and memory (Stuart et al., 2013), further support-
ing our hypothesis that the judgement bias task is sensitive
to treatments which induce subjective changes in mood in
humans.
These ﬁndings suggest that the differential time course of
effects seen in patients following treatment with delayed
versus rapid onset antidepressants is replicated in the
judgement bias task, suggesting this task has much better
predictive validity than previous methods. Importantly, we
observe effects with ketamine but not PCP, consistent with
clinical observations. Taken together with previous studies,
these data suggest the judgement bias task can better fulﬁl
the criteria proposed for assessment of an animal model.
The use of the modelling methods has also enabled us to
gain more insight into the underlying cognitive processes
which, going forward, may further add to the construct
validity of the task.
Affective biases are observed across several different
cognitive domains (Mathews and MacLeod, 2005; Clark
et al., 2009; Gotlib and Joormann, 2010; Robinson and
Roiser, 2016). Acute treatments with conventional antidepres-
sants have been shown to positively bias emotional learning
and memory and emotional interpretation in humans
without having subjective effects on mood (Harmer
et al., 2003, 2009b, 2013). In the rodent affective bias test
(Stuart et al., 2013), acute treatment with conventional,
delayed onset antidepressants also positively bias learning
and memory whilst ketamine alone has no effect (Stuart
et al., 2015). In the present study, acute treatments with
C.A. Hales et al.1278conventional antidepressants did not induce positive biases in
decision making, consistent with other work (Anderson
et al., 2013; Rygula et al., 2014a). However, treatments that
are known to induce rapid changes in mood, ketamine and
amphetamine, did induce positive judgement biases in this
rodent task, which can be dissociated from positive biases
induced by drugs causing slower onset mood through the
changes caused to diffusion model parameters. Taken
together, these ﬁndings suggest that affective biases asso-
ciated with different cognitive processes, as well as those
induced by rapid versus delayed onset antidepressants, are
likely to have different underlying neurobiology. The observa-
tion of positive judgement biases across timescales matching
subjective changes in mood means that this task, which has
been translated for use in humans (Paul et al., 2011; Anderson
et al., 2012; Schick et al., 2013, 2015), may offer a valuable
method to further investigate these differences.
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